Ex­clu­sive: Pfiz­er to in­vest $25M in­to tiny UK biotech with epi­ge­net­ics ap­proach to can­cer

Cam­bridge, UK-based start­up Cell­Cen­tric is re­ceiv­ing $25 mil­lion to fin­ish on­go­ing clin­i­cal stud­ies and get some ex­tra run­way in the form of a cash in­fu­sion from one of the world’s largest phar­mas.

Pfiz­er is giv­ing Cell­Cen­tric the funds as a strate­gic in­vest­ment, Cell­Cen­tric CEO Will West told End­points News, get­ting ac­cess to what he said would be the “in­side seat” as more da­ta ma­te­ri­al­ize.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER